XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
3 Months Ended 12 Months Ended
Nov. 16, 2024
USD ($)
Mar. 08, 2024
USD ($)
Mar. 31, 2025
USD ($)
shares
Mar. 31, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
Mar. 20, 2025
USD ($)
Nov. 30, 2024
USD ($)
Oct. 04, 2024
$ / shares
Cash and Cash Equivalent     $ 5,064,941   $ 6,506,750      
Short-Term Investments     2,307,685          
Cash, Cash Equivalents, and Short-Term Investments     $ 7,349,413   9,300,000      
Number of Operating Segments     1          
Revenue from Contract with Customer, Excluding Assessed Tax     $ 393,572 $ 334,617        
Accounts Receivable, Allowance for Credit Loss     0   0      
Deferred Tax Assets, Net     $ 19,100,000   $ 17,600,000      
Deferred Tax Assets, Valuation Allowance Coverage, Percent     100.00%   100.00%      
Share-Based Payment Arrangement [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares     6,401,581 6,100,857        
Restricted Stock Units (RSUs) [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares     96,984 191,510        
Share-Based Payment Arrangement, Option [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares     6,304,597 5,909,347        
Customer Concentration Risk [Member] | Revenue Benchmark [Member]                
Concentration Risk, Number of Suppliers     7 10        
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]                
Concentration Risk, Number of Customers     1 8        
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Significant Customers [Member]                
Concentration Risk, Significant Customers       4        
Revenue from Contract with Customer, Excluding Assessed Tax       $ 225,000        
Concentration Risk, Percentage       67.20%        
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Significant Customers [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax     $ 350,000          
Concentration Risk, Percentage     89.00%          
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | Non-US [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax     $ 48,000          
Concentration Risk, Percentage     65.80%          
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Eight Customers [Member] | Non-US [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax       $ 274,000        
Concentration Risk, Percentage       81.80%        
Customer Concentration Risk [Member] | Accounts Receivable [Member]                
Concentration Risk, Number of Customers     10          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax         $ 146,000      
Concentration Risk, Percentage     17.30%   61.50%      
Concentration Risk, Number of Customers     2   4      
Accounts Receivable, after Allowance for Credit Loss     $ 39,000          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customers [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax     $ 191,000          
Concentration Risk, Percentage     86.00%          
Concentration Risk, Number of Customers     4          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]                
Revenue from Contract with Customer, Excluding Assessed Tax         $ 146,000      
Concentration Risk, Percentage         61.50%      
Concentration Risk, Number of Customers         4      
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Two CROs [Member]                
Concentration Risk, Number of Suppliers     2          
Concentration Risk, Percentage     77.90%          
Research Services Purchased     $ 483,000          
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]                
Concentration Risk, Number of Suppliers       3        
Concentration Risk, Percentage       81.40%        
Research Services Purchased       $ 359,000        
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Two CROs [Member]                
Concentration Risk, Number of Suppliers         2      
Concentration Risk, Percentage     40.90%   58.90%      
Accounts Payable     $ 184,000   $ 284,000      
Gates Foundation [Member]                
Proceeds from Grantors $ 3,092,136              
Revenue from Contract with Customer, Excluding Assessed Tax     176,000          
Accounts Receivable, after Allowance for Credit Loss             $ 3,092,136  
CEPI [Member]                
Grant Receivable           $ 2,400,000    
Revenue from Contract with Customer, Excluding Assessed Tax     34,000          
CEPI [Member] | Fondazione Biotecnopolo di Siena (FBS) [Member]                
Grant Receivable           $ 4,500,000    
Conversion Of Convertible Notes Into Common Stock [Member]                
Debt Conversion, Original Debt, Amount     $ 910,000          
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares     556,623          
Senior Secured 2024 Notes [Member]                
Debt Instrument, Face Amount   $ 6,000,000            
Debt Instrument, Interest Rate, Stated Percentage   8.00% 8.00%          
Proceeds from Issuance of Senior Long-Term Debt   $ 5,824,000            
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares               $ 1.4